Citations

Clear

9383 citation(s) found for "Thomas, PS".

Impaired vaccine-elicited humoral protection in sepsis surviving hosts 3760
Kozurek, Emma , Kucaba, Tamara A., Kim, Caleb Y. , Skon-Hegg, Cara , Knoop, Kathryn A. , Badovinac, Vladimir P , Griffith, Thomas S.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1525 Get It

Abstract Description Sepsis, the life-threatening organ dysfunction stemming from the severe inflammatory response to systemic microbial infection, can affect humans of any age. One consequence of sepsis is the development of prolonged immunoparalysis that contributes to increased susceptibility to infection. With vaccination being an important means for protecting humans from infection throughout their lifetime, it is surprising that there has been no study performed to date assessing vaccine efficacy in sepsis survivors. We found neonatal and adult mice given an intramuscularly delivered inactivated multivalent influenza vaccine 30 days after sepsis induction had reduced total and class switched Ab titers, compared to non-septic controls. The reduced humoral response was due, in part, to impaired CD4 T cell and B cell responses to the vaccine. Reduced Ab titers were similarly seen in post-septic mice given an intranasal live-attenuated influenza vaccine. ELISpot data demonstrating reduced numbers of antibody secreting cells in the spleens of vaccinated septic mice further support the ELISA results. Moreover, mice vaccinated prior to sepsis induction also showed reduced antibody titers. Importantly, vaccinated septic mice had reduced protection to a lethal influenza challenge, demonstrated by increased mortality and viral burden in the lungs. These data collectively show how sepsis can lead to increased susceptibility to pathogens normally neutralized by vaccine-induced immunity. Funding Sources Supported by NIH/NIAID R35 GM140881; 5R01 GM139046; 1T32TR004385 Topic Categories Translational and Interventional Immunology (TI)
Streamlining laboratory serology testing for coccidioides infections using reflexive algorithms for enzyme immunoassay, immunodiffusion and complement fixation assays 2700
Kaleta, Erin, Ronz, Barbara, Grill, Francisca J. , Lake, Douglas F. , Grys, Thomas E.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.588 Get It

Abstract Description Coccidiomycosis is an endemic fungal infection caused by Coccidioides spp., and diagnosis is often made with serology. Coccidiomycosis is especially problematic for immunocompromised patients, with greater risk for disseminated infection and mortality. This study evaluated current strategies for detecting antibodies to Coccidioides, including enzyme immunoassay (EIA), immunodiffusion (ID) and complement fixation (CF) and applied a new ID assay for improved sensitivity and specificity. Clinical sensitivity and specificity studies were done using 1544 unique serum specimens for which Coccidioides EIA testing was clinically requested. A full panel of EIA IgG, EIA IgM, ID and CF was performed on each, comparing our in-house immunodiffusion assay using reagents from Cactus Bio, LLC to our current reference laboratory. Full method validation was completed, as prescribed by CLIA. Using existing reference lab testing as the standard, a sensitivity of 96.9%, specificity 85.9%, PPV 54.9%, NPV 99.4% was achieved. Additional chart review demonstrated the in-house ID improved to 98.0% sensitivity, 94.6 specificity, 84.2% PPV, 99.4% NPV. Such high NPV supports using reflex testing, which allowed our lab to eliminate hundreds of unnecessary CF referrals each month, saving diagnostic time, financial waste and lab resources. A reflexive testing algorithm paired with this enhanced ID assay is especially useful for the immunosuppressed, for which Coccidioides infections carry a greater risk. Topic Categories Translational and Interventional Immunology (TI)
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer
Nabid, Abdenour , Zapatero, Almudena, Bolla, M. , Joseph, David , Guerrero, A., Gonzalez, A. Alvarez, Segundo, Carmen González‐San , Rodríguez, María Ángeles Cabeza, Olivé, Agustí Pedro, Steigler, Allison , Souhami, Luís, Carrier, Nathalie , Armstrong, John G., Gillham, Charles, Pisansky, Thomas M. , Schipper, Matthew J. , Sandler, Howard M., Lawton, C.A., Roy, Soumyajit , Malone, Shawn , Hall, William A. , Shoag, Jonathan E. , Vince, Randy , García, Jorge A. , Mendiratta, Prateek, Valle, Luca , Dess, Robert T. , Jia, Angela Y. , Steinberg, Michael L. , Romero, Tahmineh , Kishan, Amar U. , Dess, Robert T , Zaorsky, Nicholas G. , Sun, Yilun , Zapatero, A. , Maingon, Philippe , Gonzalez San-Segundo, Carmen , Sole, Josep Maria, Efstathiou, Jason A. , Reijke, Theo M. de , Attard, Gerhardt , Morgan, Scott C. , Nguyen, Paul L. , Calaway, Adam , Barata, Pedro C. , Brown, Jason R. , Rettig, Matthew B. , Jackson, Will , Martin, Ting , Spratt, Daniel E.

Mayo Clinic

JAMA Oncology | November 20, 2025 | Volume: 12 | Issue: 1 | Pages: 58

10.1001/jamaoncol.2025.4800 | PMID 41264309 Get It

Importance The ideal duration of androgen deprivation therapy (ADT) for treating localized prostate cancer is unknown due to variable adherence and treatment durations tested in clinical trials. Objective To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy. Data Sources This individual patient data meta-analysis of 13 randomized phase 3 clinical trials evaluated the use of radiotherapy alone or with ADT. It included patients with a median follow-up of 11.3 (IQR, 9.5-14.5) years and ADT duration of 0 to 36 months. Most patients (7392 [72%]) included had National Comprehensive Cancer Network high-risk or very high-risk disease. Study Selection For this meta-analysis, a systematic literature search from 1980 to 2020 was performed in trial registries (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), MEDLINE (1966-2020), Embase (1982-2020), Web of Science, and Scopus to identify trials. Data Extraction and Synthesis Intention-to-treat and as-treated analyses were performed. The number needed to treat to prevent 1 distant metastasis at 10 years was calculated based on prognostic risk group. The analyses were conducted from January 5 to August 15, 2023. Main Outcomes and Measures The primary end point for this study was overall survival, defined as time to death or last follow-up from randomization. Secondary end points included biochemical recurrence, distant metastasis (DM), prostate cancer–specific mortality, and other-cause mortality. Results The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer–specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively. Conclusions and Relevance The results of this meta-analysis suggest that, for men with localized prostate cancer treated with definitive radiotherapy and ADT, there are relative and absolute benefits from increasing durations of ADT that help provide individualized risk estimates.
Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026) Part I: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 113-123

10.1097/ju.0000000000004842 | PMID 41263323 Get It

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part III: Treatment of Patients With Kidney and/or Ureteral Stones and Future Directions
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 132-141

10.1097/ju.0000000000004844 | PMID 41263325 Get It

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part II: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 124-131

10.1097/ju.0000000000004843 | PMID 41263322 Get It

The Case of a 28‐Year‐Old Woman With Medically Refractory Focal Epilepsy
Sharma, Rishi , Leppik, Ilo E. , Walczak, Thaddeus S., Patel, Sima , McGovern, Robert A. , Patel, Sima , Henry, Thomas R.

Mayo Clinic

Annals of Clinical and Translational Neurology | November 20, 2025 | Volume: 13 | Issue: 2 | Pages: 418-423

10.1002/acn3.70253 | PMID 41261507 Get It

ABSTRACT We present the case of a 28‐year‐old right‐handed woman with medically refractory focal epilepsy. Her seizure semiology and electroencephalography (EEG) indicated a seizure onset zone in the right central‐parietal area. However, both MRI and PET scans were unremarkable, showing no focal lesions or areas of altered metabolism. Intracranial monitoring, with extensive evaluation of both hemispheres, confirmed the seizure onset zone in the right central‐parietal region. This area not only served as the site of seizure onset but also encompassed the primary sensory cortex.
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Desai, Aakash , Habib, Hany , Khataniar, Himsikhar , Sehgal, Priya , Kochhar, Gursimran , Sehgal, Priya , Kochhar, Gursimran S , Desai, Aakash , Farraye, Francis A. , Barnes, Edward L. , Hashash, Jana G.

Mayo Clinic

Inflammatory Bowel Diseases | November 19, 2025 | Volume: 32 | Issue: 5 | Pages: 869-874

10.1093/ibd/izaf301 | PMID 41365321 Get It

Abstract Introduction There are limited data on the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) on the risk of recurrent pouchitis after ileal pouch–anal anastomosis (IPAA) for ulcerative colitis (UC). Methods A retrospective cohort study was conducted in the TriNetX Research Network in adult patients with obesity and IPAA for UC with a history of pouchitis in whom a GLP-1RA was initiated compared to those patients in whom a GLP-1RA was not initiated. The primary outcome was the risk of recurrent pouchitis within 12 months. The secondary outcomes were mean number of antibiotic prescriptions, anti-diarrheal medication use, Crohns-like disease of pouch (CLDP), and pouch excision. One-to-one propensity score matching was performed. Results We identified 43 UC-IPAA patients with obesity and history of pouchitis (mean age 51.7 ± 14.7 years, mean body mass index [BMI] 34.4 ± 6 kg/m2, 60.4% female). After propensity score matching, the GLP-1RA cohort had a significantly decreased risk of recurrent pouchitis (26.3% vs 52.6%; adjusted odds ratio [aOR], 0.32; 95% CI, 0.12-0.84) compared to the control cohort. Mean antibiotic prescriptions were numerically lower in the GLP-1RA cohort (2 vs 4.4, P = .16). Anti-diarrheal medication use was lower in the GLP-1RA cohort (18.4% vs 47.3%; aOR, 0.23; 95% CI, 0.07-0.67). There was no difference in the risk of CLDP. Zero patients required pouch excision in both cohorts. Conclusion Our study in a small cohort of patients with UC-IPAA and obesity with a history of pouchitis showed that GLP-1RA use was associated with decreased risk of recurrent pouchitis and anti-diarrheal medication use.